Spotlighting our latest completed collections & our open collections for submissions. ✅ 𝗖𝗼𝗺𝗽𝗹𝗲𝘁𝗲𝗱 𝗖𝗼𝗹𝗹𝗲𝗰𝘁𝗶𝗼𝗻𝘀: 🔎 𝙍𝙀𝙏@𝙏𝙝𝙞𝙧𝙩𝙮 - bit.ly/4p9qspY 🔬 𝙏𝙝𝙚 𝙒𝙖𝙧𝙗𝙪𝙧𝙜 𝙀𝙛𝙛𝙚𝙘𝙩 - bit.ly/4rb6eOs 💡 𝗢𝗽𝗲𝗻 𝗳𝗼𝗿 𝗦𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀: 🌱 𝙃𝙚𝙧𝙞𝙩𝙖𝙗𝙡𝙚 𝙀𝙣𝙙𝙤𝙘𝙧𝙞𝙣𝙚 𝘾𝙖𝙣𝙘𝙚𝙧𝙨 - bit.ly/43A22O7 🧠 𝙋𝙞𝙩𝙪𝙞𝙩𝙖𝙧𝙮 𝙏𝙪𝙢𝙤𝙪𝙧𝙨 - bit.ly/4p9qTk6

Please join us in welcoming Dr. Crona to the Endocrine-Related Cancer community. Dr. Crona is Associate Professor at Uppsala University, Sweden, and a clinical oncologist with a special interest in endocrine neoplasia.🚀

🏆 As we approach the end of 2025, we’re launching the Endocrine-Related Cancer Best Paper Award - celebrating the most outstanding articles published in 2025. Papers will be selected by our editorial leadership, with 1st place awarded £1000 💜 Stay tuned, selection will take place in 2026!

Today, we stand with the global community in recognising everyone affected by neuroendocrine cancer. At Endocrine-Related Cancer, we remain committed to publishing high-quality research that advances understanding of NETs to optimise patient care. 🔗 lnkd.in/eBY6uA_r #WorldNeuroendocrineCancerDay

We’re excited to announce a new Special Collection featuring the most significant clinical & scientific presentations from the 7th International Symposium on Pheochromocytoma. 🔗 For more info: lnkd.in/d3gyVVbg Collection Editors: Prof. Isabelle Bourdeau, Prof. Karel Pacak & Prof. André Lacroix

🎉 Excited to share our new publication! Targeted inhibition of netrin–DCC axis with NP137 reverses netrin-driven survival in vitro & reduces high-grade pancreatic NEN progression in vivo. Potential therapeutic strategy for aggressive PNENs? bit.ly/435pKBx @endocancer.bsky.social

Lenvatinib is preferred over sorafenib as first-line therapy for RR‑DTC due to superior PFS. Vincenzo Marotta et al. compared both MKIs in a real‑world, treatment‑naïve cohort: lenvatinib showed higher activity, but no OS benefit. Subscribers can read the article: doi.org/10.1530/ERC-24-0215

🧬 Results from clinical trial NCT03969121: Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer. Now available in Endocrine-Related Cancer #OpenAccess: doi.org/10.1530/ERC-24-0353

Early-Career Editor Opening! A great opportunity for early-career researchers to build editorial experience, gain mentorship & shape research. To apply, send your CV and cover letter to [email protected] by 7 Nov 2025. Questions? Reach out to [email protected]

New research by Di Sun et al. investigates the long-term efficacy of anlotinib in patients with progressive RAIR-DTC and explores the predictive potential of PET/CT parameters. 🔗 Subscribers of Endocrine-Related Cancer can read the full article: doi.org/10.1530/ERC-25-0027

New retrospective cohort study by Branislav Klimacek et al. explores the non-operative management of initially asymptomatic patients diagnosed with small intestine neuroendocrine tumors, raising questions about current guidelines. Read the full study here #OpenAccess: doi.org/10.1530/ERC-25-0205

Be part of the global #neuroendocrinecancer research conversation in Boston, November 17-19. The NETRF (@netrf.org) Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other. Register now: bit.ly/4nQ9goU #NETresearch #cancerresearch

Neoadjuvant Palbociclib Plus Endocrine Therapy Does Not Improve PEPI Scores in Resectable HR+ Breast Cancer #BreastCancer #BCSM @endocancer.bsky.social www.onclive.com/view/neoadju...

Explore the latest in #pheochromocytoma & #paraganglioma research with Endocrine-Related Cancer’s (@endocancer.bsky.social) special collection, featuring recent advances in genetics, metabolomics, nuclear medicine & more. Explore the collection: erc.bioscientifica.com/page/PPGL

🔬 Discovery of a novel sodium iodide symporter regulatory pathway in breast cancer cells. Vikki L Poole et al. opens new therapeutic avenues in #BreastCancer by mapping sodium iodide symporter regulation & pinpointing targets to boost radioiodide avidity. Read #OpenAccess: doi.org/10.1530/ERC-...

New research by Exequiel Gonzalo Alonso et al. uncovers a protumor role for HO-1 in thyroid cancer by enhancing proliferation, migration & cell cycle progression. 🔎 🎯Could HO-1 be a therapeutic target? Subscribers can read the research: doi.org/10.1530/ERC-25-0177 #ThyroidCancer #CancerResearch

🧠Contribute to Endocrine-Related Cancer's new Special Collection on pituitary tumours! We welcome basic, translational & clinical studies that advance understanding & showcase innovations in the field. 📩Submit your proposal to: [email protected] 🌐More info: bit.ly/4mUXslc

🎯Targeting RET in medullary thyroid cancer has played a key role in therapeutic strategies in the past decade. A new review by Kate Newbold and Leslie Cheng explores targeted and selective RET therapies, and highlights the challenge of resistance. 🔗 doi.org/10.1530/ERC-24-0291

🌱Endocrine-Related Cancer is officially on LinkedIn! Follow our new profile to stay up to date with the latest articles, special collections and updates from the journal. 🌐 linkedin.com/company/endocrine-related-cancer/ #MedSky #CancerResearch #EndocrineOncology #HormoneCancers

✨ Systems biology approaches are reshaping our understanding of cancer. Latest review by Michael V Orman et al. (@cupharmacology.bsky.social‬) highlights the successes & potential of these approaches in bettering our understanding of prostate cancer. 👉 #OpenAccess - doi.org/10.1530/ERC-25-0067

🌟We are delighted to announce that Prof. Alfred Lam, Professor of Pathology at Griffith University, has joined Endocrine-Related Cancer's editorial board as an Associate Editor. 👉 Explore his recent research article on the rising incidence of thyroid cancer: doi.org/10.1530/ERC-24-0326

Sponsored by @netrf.org, this $100,000 grant is designed to help an early-career, basic or clinical scientist conduct novel and innovative #NETs research. Learn more: mierf.org/to-apply/ #neuroendocrinecancer #earlycareerresearcher

🎯Could DNA-PKcs be a potential target for differentiated thyroid cancer therapy? Recent preclinical research by Shu-Fu Lin et al. reveals that M3814, a DNA-PKcs inhibitor, has significant potential in treating DTC. 🔗Explore the results: doi.org/10.1530/ERC-25-0031

How do treatments for neuroendocrine neoplasms impact quality of life? A new review explores the impact of existing therapies such as somatostatin analogs, radioligand therapy, multikinase inhibitors & chemotherapy on quality of life in #NEN survivors. 📖 Read more: doi.org/10.1530/ERC-24-0303

✨We are thrilled to welcome Dr. Karel Pacak as the incoming Editor-in-Chief of Endocrine-Related Cancer! Dr. Pacak's term begins on 1st January 2026. We are excited for this next chapter, driven by his expertise and vision 🚀

The special collection in @endocancer.bsky.social - "From Discovery Science to the Clinic - Heritable Endocrine Cancers and Related Disorders" is open & calling for contributions. Edited by myself, Lois Mulligan & Joanne Ngeow in memory of Prof Charis Eng erc.bioscientifica.com/page/heritab... 🧪

🧪New research by Jinheng Xiao et al. explores the distinct metabolic profiles of parathyroid carcinoma and parathyroid adenoma, identifying promising biomarkers for preoperative diagnosis of parathyroid carcinoma. Read the full article #OpenAccess: doi.org/10.1530/ERC-24-0192

Attending #ENDO2025? Come and visit the Bioscientifica booth, 803, to learn more about publishing in Endocrine-Related Cancer and pick up a booklet of recently published research 🤩🙌

Have you read the summer issue of The #Endocrinologist yet? 📰 Here are our editorial board’s picks of the ‘hot’ papers from the Society's journals and beyond. @joendocrinology.bsky.social @endocancer.bsky.social @natmetabolism.nature.com Dive into the latest hot topics here 👉 bit.ly/3TTIn6f

🧬New research by Mina Sattari et al. identifies 85 metastatic castration-resistant prostate cancer-associated genes, spotlighting TMEM18 as a promising prognostic biomarker in early prostate cancer. 👉 Explore the full article #OpenAccess: doi.org/10.1530/ERC-25-0070

So happy to see @endocancer.bsky.social has newly joined Bluesky! Of all the editorial boards I've been on, this one is a highlight for dedicated academics creating a platform for strong research in this field. Q1 in the recent journal citation reports. Great home for endocrine cancer research 🧪

👋We are thrilled to join the @bsky.app community! We spotlight novel research on endocrine neoplasias & hormone-dependent cancers. Follow us for the latest articles, themed collections & developments in endocrine oncology. 🧬Explore: erc.bioscientifica.com